Physician

Adam C Wenzlik, MD

According to 2025 Medicare claims, Adam Wenzlik, MD (NPI: 1447297049) practices family practice in the Durham-Chapel Hill, NC market, with the plurality of this provider's patient population coming from Durham, NC. This provider's primary affiliated billing organization is RALEIGH DURHAM MEDICAL GROUP PA (NPI: 1295784874; TIN: 201582408) and primary practice location at 27704-2119. Wenzlik is affiliated with the Emergent ACO, LLC (ACO ID: A4556), participating under the MSSP model.

Wenzlik's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 189 traditional Medicare patients, billed 1,936 HCPCS/CPT codes, and received $88,086 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 6,519 prescription claims across 370 beneficiaries totaling $713,257 in drug costs, led by Ozempic (Semaglutide). 2023 DME data shows 34 claims. Open Payments data shows 3 records totaling $85. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $111,614 and ending at $88,086. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $312,718 to $713,257. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $6,361 and ending at $10,880.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	292	2,988	$111,614
2016	169	3,252	$73,083
2017	172	4,131	$67,888
2018	219	3,193	$80,721
2019	238	2,026	$83,962
2020	189	2,058	$78,206
2021	282	2,283	$90,515
2022	347	3,782	$132,711
2023	341	2,603	$149,442
2024	189	1,936	$88,086

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	194	4,250	$312,718
2016	218	4,304	$326,371
2017	230	4,383	$327,416
2018	278	5,071	$399,909
2019	289	5,364	$393,349
2020	289	5,647	$555,853
2021	315	5,682	$545,942
2022	347	5,843	$583,736
2023	359	6,044	$708,882
2024	370	6,519	$713,257

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	15	139	$2,719
2016	12	192	$8,192
2017	14	165	$5,036
2018	14	146	$4,697
2019	13	112	$3,537
2020	12	108	$2,689
2021	N/R	40	$673
2022	N/R	29	$2,353
2023	N/R	34	$2,183
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	104	104	$121
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	159	368	$76
G0008	Administration of influenza virus vaccine	65	67	$30
80061	Blood test, lipids (cholesterol and triglycerides)	125	180	$13
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	70	97	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	120	5,360	$161,175
Jardiance	Empagliflozin	100	6,120	$115,260
Eliquis	Apixaban	110	5,226	$101,425
Arexvy	Rsvpref3 Antigen/As01e/Pf	79	485	$25,484
Spiriva Handihaler	Tiotropium Bromide	26	1,020	$16,862

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$85	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam C. Wenzlik, MD?

Tedicare shows public-source Medicare data for Adam C. Wenzlik, MD (NPI 1447297049), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam C. Wenzlik, MD have ACO affiliation data?

Adam C. Wenzlik, MD is shown with ACO affiliation data for Emergent ACO, LLC (MSSP, ACO ID A4556).

What billing organization is linked to Adam C. Wenzlik, MD?

Adam C. Wenzlik, MD is linked to RALEIGH DURHAM MEDICAL GROUP PA (billing NPI 1295784874) in the available physician profile data.

Does Adam C. Wenzlik, MD have Open Payments data?

Adam C. Wenzlik, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.